Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.

TY - JOUR

T1 - Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.

AU - Nast, Alexander

AU - Kopp, Ina B

AU - Augustin, Matthias

AU - Banditt, Kirstin-Benita

AU - Boehncke, Wolf-Henning

AU - Follmann, Markus

AU - Friedrich, Markus

AU - Huber, Matthias

AU - Kahl, Christina

AU - Klaus, Joachim

AU - Koza, Joachim

AU - Kreiselmaier, Inga

AU - Mohr, Johannes

AU - Mrowietz, Ulrich

AU - Ockenfels, Hans-Michael

AU - Orzechowski, Hans-Dieter

AU - Prinz, Jörg

AU - Reich, Kristian

AU - Rosenbach, Thomas

AU - Rosumeck, Stefanie

AU - Schlaeger, Martin

AU - Schmid-Ott, Gerhard

AU - Sebastian, Michael

AU - Streit, Volker

AU - Weberschock, Tobias

AU - Rzany, Berthold

PY - 2007

Y1 - 2007

N2 - Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1 to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, patient surveys have revealed lack of satisfaction with the efficacy of available treatments and a high rate of non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) initiated a project to develop evidence-based guidelines for the management of psoriasis. These resulting Guidelines focus on induction therapy in cases of mild, moderate, and severe plaquetype psoriasis in adults. The Guidelines include evidence-based evaluation of the efficacy of all currently available therapeutic options in Germany. In addition, they offer detailed information on how best to administer the various treatments and give information on contraindications, adverse drug reactions, and drug interactions as well as estimates of practicability and cost. The Guidelines were developed following the recommendations of the Arbeitsgemeinschaft wissenschaftlicher medizinischer Fachgesellschaften (AWMF). The therapeutic recommendations were developed by an expert group and finalized during interdisciplinary consensus conferences.

AB - Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1 to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, patient surveys have revealed lack of satisfaction with the efficacy of available treatments and a high rate of non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) initiated a project to develop evidence-based guidelines for the management of psoriasis. These resulting Guidelines focus on induction therapy in cases of mild, moderate, and severe plaquetype psoriasis in adults. The Guidelines include evidence-based evaluation of the efficacy of all currently available therapeutic options in Germany. In addition, they offer detailed information on how best to administer the various treatments and give information on contraindications, adverse drug reactions, and drug interactions as well as estimates of practicability and cost. The Guidelines were developed following the recommendations of the Arbeitsgemeinschaft wissenschaftlicher medizinischer Fachgesellschaften (AWMF). The therapeutic recommendations were developed by an expert group and finalized during interdisciplinary consensus conferences.

M3 - SCORING: Zeitschriftenaufsatz

VL - 5

SP - 1

EP - 119

JO - J DTSCH DERMATOL GES

JF - J DTSCH DERMATOL GES

SN - 1610-0379

IS - 3

M1 - 3

ER -